Pharmafile Logo
Pharmafocus logo
Advanced Search
novartis_outside_1

FDA approves Novartis’ Beovu injection for wet age-related macular degeneration

October 8, 2019
Manufacturing and Production, Sales and Marketing Beovu, Eylea, FDA, Novartis, Regeneron, pharma

Novartis has secured FDA approval for its Beovu (brolucizumab) injection in the treatment of wet age-related macular degeneration (AMD), it …

News

Pfizer to develop Akcea/Ionis’ Antisense Drug for up to $1.5bn

October 8, 2019
Manufacturing and Production

Pfizer and Akcea Therapeutics have entered into an exclusive worldwide licensing agreement for Akcea’s phase 2 cardiovascular and metabolic candidate …

News

Johnson & Johnson win FDA Breakthrough status for cancer drug Zejula

October 7, 2019
Sales and Marketing

The US FDA has granted breakthrough therapy designation for Johnson & Johnson’s Zejula (niraparib) for the treatment of metastic prostate …

News
merdad_parsey

Gilead appoints Merdad Parsey as Chief Medical Officer

October 7, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Gilead Sciences have announced that Merdad Parsey will join the company as Chief Medical Officer, effective November 1st. Dr Parsey …

Appointment

Breaking through limits in lung cancer: Introducing the Lung Ambition Alliance

October 7, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Lung Ambition Alliance, feature, lung cancer, pharma

Lung cancer kills more patients than any other variety of cancer, accounting for around a fifth of all cancer-related deaths …

Feature
oxycontinoverdoses_798

Sacklers made up to $13 billion in profits from Purdue Pharma

October 7, 2019
Sales and Marketing

New court records filed in Purdue Pharma’s ongoing bankruptcy case show that the owners, the Sackler family, received $12 billion …

News
merckwindow_web

Scotland approves first-line NHS use of MSD’s Keytruda combo for advanced non-small cell lung cancer

October 7, 2019
Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, keytruda, lung cancer, pharma

The Scottish Medicines Consortium (SMC) has announced its decision to accept MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) in combination with pemetrexed …

News

Pfizer reports positive phase 3 data in atopic dermatitis

October 7, 2019
Sales and Marketing

Pfizer has announced top-line results from a second Phase 3 study evaluating the efficacy and safety of its oral JAK1 …

News
7359dba7-e1da-4eb4-8765-58da6178899b

Sarepta’s investigational gene therapy shows strength in limb-girdle muscular dystrophy Type 2E

October 7, 2019
Research and Development, Sales and Marketing muscular dystrophy, pharma, sarepta

Sarepta Therapeutics has revealed positive new data for its investigational gene therapy SRP-9003 in the treatment of limb-girdle muscular dystrophy …

News
galderma

Galderma wins FDA approval for new retinoid molecule acne treatment AKLIEF

October 7, 2019
Sales and Marketing

Galderma, a global leader in skin health, has announced that the FDA has approved the First New Retinoid Molecule for …

News
jj_sign_on_wall

Johnson & Johnson commits $500m to end HIV and TB Epidemics

October 4, 2019
Medical Communications, Research and Development

Johnson & Johnson have announced it has committed to ensuring more than $500 million is dedicated to R&D delivery programs …

News
top_10_photo

Top Ten most popular articles on Pharmafile.com this week

October 4, 2019
Medical Communications

Another week comes to an end at Pharmafile and we run down with the top 10 articles for the week. …

News
shutterstock_212432119

Arbutus Biopharma moves to terminate development of chronic hepatitis B therapy after trial failure

October 4, 2019
Medical Communications, Research and Development Arbutus Biopharma, hepatitis B, pharma

Arbutus Biopharma has announced its decision to terminate the development of its oral capsid inhibitor, known as AB-506, in the …

News
cma-logo-v3

UK watchdog finds drug firms colluded to hike essential NHS medication by 1,800%

October 4, 2019
Medical Communications

The UK’s Competition and Markets Authority (CMA) has provisionally found that three drug firms signed an illegal agreement which led …

News
astrazeneca_building_white

FDA approves single-use auto-injector form of IL-5 inhibitor Fasenra

October 4, 2019
Medical Communications, Sales and Marketing AstraZeneca, FDA, Fasenra, pharma

AstraZeneca is celebrating as the FDA announced the approval of its IL-5 inhibitor Fasenra  (benralizumab) in a pre-filled, single-use auto-injector …

News
gilead-sciences

FDA approves second PrEP drug to prevent HIV infection

October 4, 2019
Medical Communications

The US FDA has approved Gilead’s Descovy (emtricitabine/tenofovir alafenamide) as a second pre-exposure prophylaxis (PrEP) drug in at-risk adults and …

News
servier

Servier gains non-Hodgkin lymphoma drug from CTI BioPharma

October 3, 2019
Medical Communications, Sales and Marketing

French pharma-giant Servier has purchased the medication Pixuvri, indicated for the treatment of non-Hodgkin B-cell lymphoma, from US-based CTI BioPharma. …

News
emma-walmsley-big

GSK Chief Emma Walmsley voices support for equal pay campaign

October 3, 2019
Medical Communications Emma Walmsley, GSK, GlaxoSmithKline, pharma

GlaxoSmithKline Chief Emma Walmsley has joined the chorus of more than a hundred of the UK’s most successful female business …

News
novartis_side_building

Novartis selects Microsoft for AI drug development

October 3, 2019
Research and Development

Novartis has begun an alliance with Microsoft to leverage the latter’s artificial intelligence (AI) technology for the discovery, development and …

News
rocherooflr

NICE rejects Roche’s immunotherapy Tecentriq in unresectable metastatic triple A breast cancer

October 3, 2019
Sales and Marketing Cancer, NICE, Roche, breast cancer, pharma, tecentriq

NICE has revealed its decision not to approve Roche’s immunotherapy Tecentriq (atezolizumab) for use on the NHS in England and …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026